Testosterone Cypionate vs Testosterone Enanthate: Head-to-Head Efficacy

What Makes These Two Esters Different at the Molecular Level

Both testosterone cypionate and testosterone enanthate deliver the same parent hormone. The only structural distinction is the carboxylic acid esterified at the 17-beta hydroxyl group: cypionate uses cyclopentylpropionic acid (8 carbons), while enanthate uses heptanoic acid (7 carbons) 1. That single carbon difference changes the lipophilicity of the molecule by a small margin, which modestly alters how quickly the ester cleaves in tissue.

Once injected intramuscularly, esterases in the muscle depot and bloodstream hydrolyze either ester to release free testosterone. The testosterone molecule that reaches androgen receptors is chemically identical regardless of which ester carried it. No downstream metabolite of the ester portion has known androgenic or anti-androgenic activity. The clinical implication is straightforward: any difference between these formulations is pharmacokinetic, not pharmacodynamic.

The carrier oil does differ between branded products. Depo-Testosterone (cypionate) uses cottonseed oil, while Delatestryl (enanthate) uses sesame oil 2. Patients with seed-oil allergies occasionally have injection-site reactions tied to the vehicle, not the testosterone ester itself. Generic manufacturers may use alternative oils, so checking the package insert matters for patients with known sensitivities.

Pharmacokinetics: Half-Life, Peak, and Trough Patterns

Testosterone cypionate has a reported terminal half-life of approximately 8 days, while enanthate sits around 4.5 days 3. These numbers come from single-dose pharmacokinetic studies. The practical gap narrows at steady state.

With weekly injections of 100 mg, both esters produce peak serum testosterone between 24 and 72 hours post-injection and trough values at 6 to 7 days. A pharmacokinetic modeling study by Behre and Nieschlag found that after 4 to 6 weeks of weekly dosing, trough-to-peak fluctuations for cypionate and enanthate overlapped substantially 3. The slightly longer half-life of cypionate can produce marginally higher trough levels (roughly 50 to 80 ng/dL higher in some patients on equivalent doses), but this difference rarely changes clinical decision-making.

For men injecting every 14 days (a common but increasingly discouraged schedule), the longer half-life of cypionate offers a modest advantage. Day-12 and day-13 troughs tend to dip less dramatically with cypionate. The 2018 Endocrine Society guideline recommends injection intervals of 7 to 14 days for both esters, acknowledging that shorter intervals reduce symptomatic troughs 1.

Subcutaneous injection of either ester has gained traction. A 2017 study by Al-Futaisi et al. showed that subcutaneous cypionate at 50 to 80 mg weekly maintained total testosterone between 400 and 900 ng/dL in 95% of subjects 4. Comparable subcutaneous data for enanthate exist primarily from European TRT protocols, with similar steady-state profiles. The route of injection appears to matter more than the ester choice for controlling peak-to-trough swings.

Clinical Efficacy: What the Evidence Actually Shows

No randomized controlled trial has directly compared testosterone cypionate against testosterone enanthate for any clinical endpoint. This is worth stating plainly. Every efficacy comparison between these esters is indirect, drawn from parallel studies that used one formulation or the other against placebo or against baseline.

The T-Trials, a coordinated set of seven placebo-controlled trials published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL 5. These trials used transdermal testosterone gel (AndroGel 1%), not injectable esters. They demonstrated significant improvements in sexual function (effect size 0.45, P<0.001), physical function measured by 6-minute walking distance (+14.3 meters over placebo), and self-reported vitality scores. The T-Trials remain the largest coordinated evidence base for TRT benefits, but they cannot adjudicate between injectable esters.

For injectable-specific data, a 2016 meta-analysis by Corona et al. pooled 37 RCTs involving various testosterone formulations and found that injectable esters (cypionate and enanthate combined) produced the largest improvements in total testosterone levels (weighted mean increase of 370 ng/dL) and the most consistent improvements in sexual desire scores compared with gels and patches 6. The meta-analysis did not separate cypionate from enanthate outcomes because the included studies treated them as interchangeable.

The American Urological Association's 2018 guideline on testosterone deficiency states: "Injectable testosterone esters (cypionate and enanthate) are effective, well-established treatments for testosterone deficiency. There is no evidence to support the superiority of one ester over the other" 7. Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School and a lead investigator in TRT research, has noted: "Cypionate and enanthate are so pharmacologically similar that the choice between them is more a matter of geography and habit than medicine."

Side Effect Profiles: Are There Meaningful Differences

The adverse-effect profiles of testosterone cypionate and enanthate are, for clinical purposes, the same. Both carry the class-level risks of exogenous testosterone: erythrocytosis, acne, reduced HDL cholesterol, suppression of spermatogenesis, and potential effects on cardiovascular risk 1.

Erythrocytosis is the most common lab abnormality requiring intervention. The Endocrine Society guideline recommends monitoring hematocrit at baseline, 3 to 6 months, and then annually, with a threshold of 54% for dose reduction or temporary cessation 1. This threshold applies identically to both esters. In the TRAVERSE trial (N=5,246), which used a topical gel formulation, the rate of major adverse cardiovascular events did not differ significantly between testosterone and placebo (HR 0.99 to 95% CI 0.81 to 1.21) over a mean follow-up of 33 months 8. While TRAVERSE used gel rather than injections, it provides the most definitive cardiovascular safety data for TRT to date.

One practical distinction exists at the injection site. Cottonseed oil (cypionate's typical vehicle) has a higher reported rate of injection-site erythema and nodule formation in patients with cottonseed sensitivity. Sesame oil (enanthate's typical vehicle) causes reactions less frequently overall, but sesame allergy, though rare, can be severe. Neither vehicle-related reaction reflects a property of the testosterone ester.

Estradiol conversion rates do not differ meaningfully between the two esters. Both are aromatized at the same rate once free testosterone is released. Patients experiencing estrogen-mediated side effects (gynecomastia, water retention, mood changes) on one ester will experience the same on the other at equivalent doses.

Dosing Protocols and Injection Frequency

Standard prescribing for both esters falls within 100 to 200 mg intramuscularly every 7 to 14 days. The Endocrine Society recommends targeting a mid-normal total testosterone range of 450 to 600 ng/dL, measured as a trough value drawn immediately before the next injection 1.

Weekly injections of 100 mg produce more stable serum levels than biweekly injections of 200 mg. This holds true for both esters. A crossover study by Amory et al. (2004) demonstrated that 200 mg biweekly injections of enanthate produced supraphysiologic peaks above 1 to 100 ng/dL at 48 hours and sub-therapeutic troughs below 300 ng/dL by day 12 in 40% of subjects 9. Splitting the same total dose into weekly 100 mg injections eliminated both the peaks and the troughs.

Some clinicians prescribe every-3.5-day injections (50 mg twice weekly) for patients who are sensitive to fluctuations. This protocol works well with either ester, though the slightly shorter half-life of enanthate makes it a marginally better match for twice-weekly dosing from a pure pharmacokinetic standpoint. The difference is small enough that patient preference and injection comfort should drive the decision.

Subcutaneous protocols typically use smaller volumes (0.3 to 0.5 mL) with insulin syringes. Both esters in their standard 200 mg/mL concentrations are suitable for subcutaneous delivery. Absorption is slightly slower subcutaneously, which can reduce peak-to-trough variation by an additional 10 to 15% compared with intramuscular injection of the same dose 4.

Cost, Insurance Coverage, and Availability

In the United States, testosterone cypionate dominates the market. Generic cypionate (200 mg/mL, 10 mL multi-dose vial) costs approximately $30 to $90 at retail pharmacies without insurance. Generic enanthate in the same concentration and volume falls within a similar range but is stocked less consistently 2.

Insurance formularies in the US almost universally cover cypionate as a Tier 1 or Tier 2 generic. Enanthate coverage is less predictable. Some pharmacy benefit managers classify it as non-preferred, requiring prior authorization or a higher copay. This administrative friction, not any clinical inferiority, is why most US prescribers default to cypionate.

Outside the United States, the pattern reverses. Testosterone enanthate (marketed as Testoviron Depot in many countries) is the standard injectable ester in Europe, Latin America, and parts of Asia. Cypionate has limited availability in these regions. A patient relocating internationally should expect to switch esters based on local formulary access.

Compounding pharmacies in the US offer both esters, often in custom concentrations (e.g., 100 mg/mL or 250 mg/mL) and alternative carrier oils (grapeseed, MCT). Compounded formulations are typically not FDA-approved, and quality can vary between pharmacies. The Endocrine Society's 2018 guideline recommends FDA-approved formulations when available 1.

How to Switch Between Cypionate and Enanthate

Switching is straightforward. Because both esters deliver the same active hormone at comparable rates, a milligram-for-milligram swap is the standard approach. A patient taking 100 mg of cypionate weekly can transition to 100 mg of enanthate weekly without a washout period or dose adjustment.

The AUA guideline does not require additional monitoring beyond the standard protocol when switching between these two esters 7. A follow-up trough testosterone level at 4 to 6 weeks after the switch confirms that levels remain in the target range. Minor adjustments of 10 to 20 mg may be needed in individual patients, but this reflects normal biological variability rather than a systematic difference between the esters.

Patients occasionally report subjective differences after switching. These reports are common in online forums but lack controlled evidence. Potential explanations include the change in carrier oil (which affects injection-site discomfort and absorption rate), a placebo or nocebo effect, or coincidental changes in other variables (sleep, stress, diet). If a patient strongly prefers one ester, there is no clinical reason to override that preference.

Dr. Mohit Khera, Professor of Urology at Baylor College of Medicine and a contributor to the AUA testosterone guideline, has stated: "When patients tell me they feel different on cypionate versus enanthate, I take that seriously, but I also explain that the pharmacology gives us no reason to expect a difference. We adjust the dose, check the levels, and go from there."

Which Ester Should You Choose

For most men starting TRT in the United States, testosterone cypionate is the practical default. It is more widely stocked, more reliably covered by insurance, and equally effective. For men outside the US or those with cottonseed oil sensitivity, enanthate is the logical first choice 1.

If you are already stable on one ester with good lab values and no side effects, there is no clinical reason to switch. If you experience injection-site reactions, ask your prescriber about the carrier oil in your current formulation before changing esters. The oil, not the ester, is the more likely culprit.

Men injecting twice weekly who want the flattest possible pharmacokinetic curve may find a marginal theoretical advantage with enanthate's shorter half-life, but this difference is too small to measure clinically in most patients. The 2018 Endocrine Society guideline treats both esters as fully interchangeable first-line options for injectable TRT, with target trough total testosterone of 450 to 600 ng/dL 1.